TRATAMIENTO PALIATIVO DEL DOLOR CON QUADREMET EN PACIENTES CON METASTASIS OSEAS OSTEOBLASTICAS.

[ 177 Lu]Lu-DOTA-TATE and [ 131 I]MIBG Phenotypic Imaging-Based Therapy in Metastatic/Inoperable Pheochromocytomas and Paragangliomas: Comparative Results in a Single Center.

Prado-Wohlwend, Stefan; (...); Merino-Torres, Juan Francisco

Article. 10.3389/fendo.2022.778322. 2022

• 
• 
• 16

  

177Lu-DOTATATE (PRRT) in the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEPNETs) versus other tumors

Jimenez-Fonseca, P.; (...); Carmona-Bayonas, A.

Meeting Abstract. 2022

177-Lu-DOTATATE in 382 patients with somatostatin receptor-positive advanced tumors: Real-world data from the SEPTRALU registry

Casanovas M, Mitjavila; (...); Carmona-Bayonas, A.

Meeting Abstract. 2022

177Lu-DOTATATE in advanced neuroendocrine neoplasms of different locations - Data from 552 cases in the SEPTRALU registry

Mitjavila Casanovas, M.; (...); Jimenez-Fonseca, P.

Meeting Abstract. 2023

Alternatives of the pelvic sentinel lymph node migration pathway in early ovarian cancer: the simplest the best.

Lago, Victor; (...); Domingo, Santiago

Article. 10.1136/ijgc-2023-004912. 2023

• 
• 
• 2

  

BCAS1 defines a heterogeneous cell population in diffuse gliomas.

Morales-Gallel, Raquel; (...); Garcia-Verdugo, Jose Manuel

Article. 10.18632/oncotarget.28553. 2024

Clinical experience of whole body and tumour dosimetry of 131-I-mIBG treatment for pediatric patients

Espallardo, I. Torres; (...); Prado-Wohlwend, S.

Meeting Abstract. 2023

ComBat harmonization in different PET imaging scenarios

Gandia-Ferrero, M.; (...); Marti-Bonmati, L.

Meeting Abstract. 2023

Comparison of 3D dosimetry methods in hepatic radioembolisation with Y-90 microspheres

Carrasco Vela, N.; (...); Torres-Espallardo, I.

Meeting Abstract. 2021

Comparison of protocols with respiratory-gated (4D) motion compensation in PET/CT: open-source package for quantification of phantom image quality.

Martinez-Movilla, Andrea; (...); Carles, Montserrat

Article. 10.1186/s40658-022-00509-4. 2022

• 
• 
• 3

  

Correlation Between Clinical Characteristics And Effective Washout Time In Patients Treated With High Radioiodine Activities

Guerrero Calatayud, C.; (...); Bello Arques, P.

Meeting Abstract. 2023

Do SPECT CT and sentinel node tecnhique increase the diagnosis of metastasic disease in prostate cancer?

Perez Ardavin, J.; (...); Vera-Donoso, C. D.

Meeting Abstract. 2022

Efficacy and Safety of 177Lu-DOTATATE in Lung Neuroendocrine Tumors: A multicenter study

Mitjavila Casanovas, M.; (...); Jimenez-Fonseca, P.

Meeting Abstract. 2023

Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study.

Mitjavila, Mercedes; (...); Carmona-Bayonas, Alberto

Article. 10.1007/s00259-023-06166-8. 2023

• 
• 
• 31

  

Evaluation of 177Lu-DOTATATE treatment in patients with metastasic or unresectable paragangliomas and pheochromocytomas

Canon Sanchez, J.; (...); Utrera Costero, A.

Meeting Abstract. 2021

Less is more: Usefulness of the sentinel node technique in radical prostatectomy

Perez Ardavin, J.; (...); Vera-Donoso, C. D.

Meeting Abstract. 2022

Local detection of microvessels in IDH-wildtype glioblastoma using relative cerebral blood volume: an imaging marker useful for astrocytoma grade 4 classification.

Álvarez-Torres MDM; (...); Garcia-Gomez, Juan Miguel

Article. 10.1186/s12885-021-09117-4. 2022

• 
• 
• 10

  

Lu-177-DOTATATE therapy in advanced pancreatic neuroendocrine tumors: data from 187 patients of the national registry SEPTRALU

Mitjavila-Casanovas, M.; (...); Jimenez-Fonseca, P.

Meeting Abstract. 2022

Lutetium177 in patients with stage IV neuroendocrine tumours of any origin. Data from 321 patients of the multicenter national registry

Mitjavila Casanovas, M.; (...); Jimenez-Fonseca, P.

Meeting Abstract. 2021

Medical imaging clinical trials unit: A professional need.

Penades-Blasco, Ana; (...); Marti-Bonmati, Luis

Article. 10.1016/j.ejrad.2021.110099. 2022

• 
• 1

  

Peptide Receptor Radionuclide Therapy with [(177)Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions.

del Olmo-Garcia, Maria I.; (...); Merino-Torres, Juan F.

Article. 10.3390/cancers14030584. 2022

• 
• 
• 20

  

Peptide receptor radionuclide therapy with [(177)Lu]Lu-DOTA-TATE.

Prado-Wohlwend S; (...); Endocrinology Working Group of the SEMNIM

Article. 10.1016/j.remnie.2021.11.001. 2022

• 3

  

Peptide receptor radionuclide therapy with [Lu-177]Lu-DOTA-TATE

Prado-Wohlwend, S.; (...); SEMNIM

Article. 2022

Prediction of patient progression-free survival with ¹⁷⁷Lu-DOTATATE in clinical practice: NEPTUNESEPTRALU model for patient selection

Mitjavila Casanovas, M.; (...); Carmona-Bayonas, A.

Meeting Abstract. 2024

Prognostic factors in patients with advanced neuroendocrine neoplasia treated with radiopeptides (PRRT) - Data from the national registry SEPTRALU

Bello, P.; (...); Carmona-Bayonas, A.

Meeting Abstract. 2023

Proposal of a short acquisition protocol for ¹⁸F-DOPA imaging in brain tumors:preliminary results

Orrego, N.; (...); Bello-Arques, P.

Meeting Abstract. 2024

Radio theranostics in paragangliomas and pheochromocytomas

Wohlwend, S. Prado, Arques, P. Bello

Article. 10.1016/j.remn.2024.500017. 2024

Radio theranostics in paragangliomas and pheochromocytomas.

Wohlwend SP, Arques PB

Article. 10.1016/j.remnie.2024.500017. 2024

• 
• 1

  

Radioembolization in patients with hepatocellular carcinoma: a series of 53 cases.

Olivan-Sasot, P; (...); Olivas-Arroyo, C

Article. 10.1016/j.rxeng.2021.03.001. 2023

• 
• 1

  

Response to targeted radionuclide therapy with [131I]MIBG AND [177Lu]Lu-DOTA-TATE according to adrenal vs. extra-adrenal primary location in metastatic paragangliomas and pheochromocytomas: A systematic review.

Prado-Wohlwend, Stefan; (...); Merino-Torres JF

Article. 10.3389/fendo.2022.957172. 2022

• 
• 
• 14

  

Retreatment PRRT with 177Lu-DOTATATE in patients with progressive neuroendocrine neoplasm: Spanish clinical experience from national registry

Mitjavila Casanovas, M.; (...); Hernando, J.

Meeting Abstract. 2024

Same-day comparative protocol PET/CT-PET/MRI [68Ga]Ga-DOTA-TOC in paragangliomas and pheochromocytomas: an approach to personalized medicine.

Prado-Wohlwend, Stefan; (...); Merino-Torres, Juan Francisco

Article. 10.1186/s40644-023-00521-6. 2023

• 
• 
• 6

  

Sequential treatment of High-risk Neuroblastoma combining I-131 MIBG high-dose and Topotecan. First experience

Orrego, N.; (...); Bello-Arques, P.

Meeting Abstract. 2023

Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms.

Del Olmo-Garcia MI; (...); Merino-Torres JF

Article. 10.3390/biomedicines9121810. 2021

• 
• 
• 11

  

The Role of Imaging Studies in Favor of Possible Cerebellar Multiple System Atrophy: A Case Study.

Utrera-Costero, Ana; (...); Bello-Arques, Pilar

Article. 10.1097/RLU.0000000000003767. 2021

• 
• 1

  

The sentinel node with technetium-99m for prostate cancer. A safe and, mature new gold standard?

Perez-Ardavin J; (...); Vera-Donoso CD

Article. 10.23736/S1824-4785.22.03416-1. 2022

• 
• 3

  

The value of F-18-FDG PET/CT in two cases of Primary Pericardial Mesothelioma

Utrera-Costero, Ana; (...); Bello-Arques, Pilar

Article. 10.1007/s12350-021-02690-y. 2021

Update on iodine-refractory differentiated thyroid carcinoma

Casas, E. Abou Jokh; (...); Casas, J. A. Vallejo

Article. 10.1016/j.remn.2023.06.005. 2023

Update on iodine-refractory differentiated thyroid carcinoma.

Jokh Casas, E A; (...); Vallejo Casas, J A

Article. 10.1016/j.remnie.2023.07.003. 2023

Y-90 PET/MR imaging optimization with a Bayesian penalized likelihood reconstruction algorithm.

Calatayud-Jordan, Jose; (...); Torres-Espallardo, Irene

Article. 10.1007/s13246-024-01452-7. 2024